Sitagliptin (trade names: Januvia and Xelevia) is approved for certain adults with type 2 diabetes mellitus whose blood-glucose levels are inadequately controlled by diet and exercise alone. The fixed ...

Insulin is needed less frequently and HbA1c is lowered more robustly when adults with type 2 diabetes do not delay combination therapy but begin treatment by taking sitagliptin and metformin together, ...

The study assessed the safety and efficacy of adding JANUVIA (sitagliptin) 100 mg once-daily or dapagliflozin 10 mg once-daily to treatment of patients with mild renal impairment (eGFR ≥60 and <90 ...

Results of the study demonstrated that therapy with ONGLYZA 5 mg was non-inferior to JANUVIA 100 mg when added to metformin (difference in adjusted mean change from baseline vs. JANUVIA plus metformin ...

With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...

Sitagliptin is prescribed metformin januvia 50mg people who still have high blood sugar, even though they have a sensible diet and exercise regularly. It comes as tablets that you swallow. Common side ...

With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin ...

Positive Opinion For Type 2 Diabetes Treatment, JANUVIA - First In New Class Of Oral Treatments Known As DPP-4 Inhibitors, European Union JANUVIA (sitagliptin), Merck, Sharp & Dohme's treatment for ...

These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505 (b) (2) route. The Zituvio range of products contain active ingredients ...